The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Generic semaglutide (the biosimilar version of Ozempic) is running out at pharmacies across Quebec due to recalls and surging demand. If you're currently on this medication or planning to start, here's what the shortage means for your treatment and what alternatives exist.
Singapore has approved Wegovy (semaglutide) as the first medication specifically indicated for MASH with liver fibrosis, a serious liver condition affecting millions globally. This expands the growing body of evidence that GLP-1 medications do far more than help with weight loss. Here is what patients and those considering GLP-1 therapy need to know.
Medicare's GLP-1 coverage program has reached 700,000 seniors, with Eli Lilly capturing roughly 70% of that market. This milestone signals a major shift in how older Americans access weight loss and diabetes medications, but navigating the coverage details still takes work.
When Indian MP Pappu Yadav's leaner appearance went viral in September 2026, social media filled with Ozempic speculation, though he has not confirmed using any medication. This article explains what Ozempic and Wegovy are, what results and side effects look like, current costs, and how to move from curiosity to an informed decision.
The Wegovy pill grew from 18,410 prescriptions in its first full week to roughly 172,000 a week by August 2026. This article explains the approval, OASIS 4 results, strict dosing rules, how it compares with the injection and Foundayo, and current self pay prices.
With about 1 in 8 U.S. adults currently taking a GLP-1, retailers are seeing shifts in clothing sizes and wardrobe demand. This article covers the latest Circana and KFF data, the size inclusivity debate, stigma, maintenance, current prices, and what the cultural shift means for patients.
A September 2026 Nature study found that semaglutide started late in life slowed signs of aging and extended median lifespan by about 92 days in female mice. This article explains the findings, the calorie restriction comparison, the limits of mouse research, and how it fits with human evidence.
Novo Nordisk's shares have fallen as Eli Lilly gains market share, prices fall, and semaglutide patents near expiry. This article explains what investors are worried about, why your Ozempic or Wegovy prescription is not at risk, and how competition is lowering patient costs.